1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Global Gene Therapy Partnering Terms and Agreements 2010 to 2016

Global Gene Therapy Partnering Terms and Agreements 2010 to 2016

  • October 2016
  • -
  • Currentpartnering
  • -
  • 231 pages

The Global Gene Therapy Partnering Agreements 2010-2016 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in gene therapy partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Gene therapypartnering contract documents
Top gene therapy deals by value

The Global Gene Therapy Partnering Terms and Agreements 2010-2016 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Gene therapy dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Gene therapy dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Gene therapy deals since 2010. Deals are listed by headline value, signed by big pharma, most active Gene therapy dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Gene therapy dealmaking with a brief summary followed by a comprehensive listing of Gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Gene therapy technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gene therapy technologies and products.

Report scope

Global Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.

Global Gene Therapy Partnering Terms and Agreements includes:

Trends in gene therapy dealmaking in the biopharma industry since 2010
Analysis of gene therapy deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life gene therapy deals
Access to over 200 gene therapy deals
The leading gene therapy deals by value since 2010
Most active gene therapy dealmakers since 2010
The leading gene therapy partnering resources

In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Table Of Contents

Global Gene Therapy Partnering Terms and Agreements 2010 to 2016
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gene therapy dealmaking

2.1. Introduction
2.2. Gene therapy partnering over the years
2.3. Most active Gene therapy dealmakers
2.4. Gene therapy partnering by deal type
2.5. Gene therapy partnering by therapy area
2.6. Deal terms for Gene therapy partnering
2.6.1 Gene therapy partnering headline values
2.6.2 Gene therapy deal upfront payments
2.6.3 Gene therapy deal milestone payments
2.6.4 Gene therapy royalty rates

Chapter 3 - Leading Gene therapy deals

3.1. Introduction
3.2. Top Gene therapy deals by value

Chapter 4 - Most active Gene therapy dealmakers

4.1. Introduction
4.2. Most active Gene therapy dealmakers
4.3. Most active Gene therapy partnering company profiles

Chapter 5 - Gene therapy contracts dealmaking directory

5.1. Introduction
5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking

Appendices

Appendix 1 - Gene therapy deals by company A-Z

Appendix 2 - Gene therapy deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Gene therapy deals by deal type

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative RandD
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Research
Spin out
Sub-license
Supply
Technology transfer

Appendix 4 - Gene therapy deals by therapy area

Cardiovascular
Central Nervous System
Genetic disorders
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

Appendix 5 -Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Gene therapy partnering since 2010
Figure 2: Active Gene therapy dealmaking activity- 2010 to 2016
Figure 3: Gene therapy partnering by deal type since 2010
Figure 4: Gene therapy partnering by disease type since 2010
Figure 5: Gene therapy deals with a headline value
Figure 6: Gene therapy deals with an upfront value
Figure 7: Gene therapy deals with a milestone value
Figure 8: Gene therapy deals with a royalty rate value
Figure 9: Top Gene therapy deals by value since 2010
Figure 10: Most active Gene therapy dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Regenerative medicines are capable of restoring the functionality of cells & tissues by treating a patient with laboratory grown cells and tissues. Regenerative medicines are used in a wide range of degenerative ...

Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026

Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026

  • $ 2349
  • Industry report
  • October 2016
  • by Roots Analysis Private Ltd.

INTRODUCTION Gene therapy has emerged as a promising treatment option for various diseases (primarily the ones that currently have no cure) including cancers, inherited disorders and some viral infections. ...

Integrase Inhibitors -Pipeline Insights, 2016

Integrase Inhibitors -Pipeline Insights, 2016

  • $ 1250
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “Integrase Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Integrase Inhibitors. The DelveInsight’s ...

Trends In Gene Therapy

July 2016 $ 5000

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.